CGEN:TLV
Compugen Ltd
ILA 616.00
arrow_downward
-8.36%(-56.20) 1D
Jun 3, 5:26:00 PM GMT+3 · ILA
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CGEN...
Open
ILA 663.00
High
ILA 675.00
Low
ILA 613.10
Mkt. cap
207.07M
Avg. vol.
55.91K
Volume
64.47K
P/E ratio
5.81
52-wk high
ILA 924.00
52-wk low
ILA 435.00
EPS
ILA 1.06
Shares outstanding
94.55M
No. of employees
75
Open
ILA 663.00
High
ILA 675.00
Low
ILA 613.10
Mkt. cap
207.07M
Avg. vol.
55.91K
Volume
64.47K
P/E ratio
5.81
52-wk high
ILA 924.00
52-wk low
ILA 435.00
EPS
ILA 1.06
Shares outstanding
94.55M
No. of employees
75
News stories
From sources across the web
Yahoo Finance
·
1 hour ago
Why The Narrative Around Compugen (NasdaqCM:CGEN) Is Shifting After Analyst Resets And New Views
Profile
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
About Compugen Ltd
AI content may include mistakes. Learn more